Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Genetic Variations in Multiple Myeloma with Extramedullary Disease

Dajung Kim, Seri Jeong, Kevin Song, Jae-Cheol Jo, JiHyun Lee, Jee-Yeong Jeong, Ho Sup Lee

Blood (2023) 142 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2023-181468

Published: 2023

Journal Articles

Real-World Outcomes of Pfts in Screening for Lung Involvement in Chronic Gvhd Post-Allogeneic Stem Cell Transplant: A Retrospective Study of 387 Patients in British Columbia, Canada

Bo Wan, Yasser Abou Mourad, Shanee Chung, Donna L. Forrest, Florian Kuchenbauer, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Maryse Power, Judith Anula Rodrigo, David Sanford, Kevin Song, Ryan J Stubbins, Heather J. Sutherland, Cynthia L. Toze, Jennifer White, Claudie Roy, Kevin A Hay

Blood (2023) 142 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2023-185055

Published: 2023

Journal Articles

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Blood (2023) 142 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2023-174338

Published: 2023

Journal Articles

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, Engin Gul, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez-Zepeda, Kevin Song, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Martha L Louzada, Richard LeBlanc

Blood (2023) 142 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2023-181138

Published: 2023

Journal Articles

Improvement in Survival of Patients with FLT3 Mutated Acute Myeloid Leukemia: Results from a Retrospective Canadian Cohort

Shouriyo Ghosh, Florian Kuchenbauer, Ryan J Stubbins, Shanee Chung, Sujaatha Narayanan, Thomas J. Nevill, Kevin Song, Judith Anula Rodrigo, Jennifer White, Claudie Roy, Yasser Abou Mourad, Stephen H. Nantel, Donna L. Forrest, Cynthia L. Toze, Kevin A Hay, Maryse Power, David Sanford

Blood (2023) 142 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2023-182466

Published: 2023

Journal Articles

British Columbia Experience in Allogeneic Stem Cell Transplantation for Myelofibrosis with or without Pre-Transplant Ruxolitinib

Shanee Chung, Ashley Kate McEwan, Yasser Abou Mourad, Donna L. Forrest, Kevin Hay, Florian Kuchenbauer, Stephen H. Nantel, Thomas J. Nevill, Judith Anula Rodrigo, Claudie Roy, David Sanford, Kevin Song, Ryan J Stubbins, Cynthia L. Toze, Jennifer White, Sujaatha Narayanan

Blood (2023) 142 (Supplement 1): 6972.

https://doi.org/10.1182/blood-2023-190446

Published: 2023

Journal Articles

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 4287–4289.

https://doi.org/10.1182/blood-2022-168843

Published: 2022

Journal Articles

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 289–291.

https://doi.org/10.1182/blood-2022-158219

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Richard Leblanc, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Michael P. Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha L Louzada, Hira S Mian, Darrell J White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7192–7194.

https://doi.org/10.1182/blood-2022-158679

Published: 2022

Journal Articles

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10002–10004.

https://doi.org/10.1182/blood-2022-163661

Published: 2022

Journal Articles

Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study

Blood (2022) 140 (Supplement 1): 7555–7557.

https://doi.org/10.1182/blood-2022-163594

Published: 2022

Journal Articles

Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

Jessica L. Bazin, Yasser Abou Mourad, Donna L. Forrest, Kevin Hay, Florian Kuchenbauer, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Maryse Power, Judith A Rodrigo, Claudie Roy, David Sanford, Kevin Song, Ryan J. Stubbins, Heather J. Sutherland, Cynthia L. Toze, Jennifer White, Shanee Chung

Blood (2022) 140 (Supplement 1): 7718–7720.

https://doi.org/10.1182/blood-2022-165411

Published: 2022

Journal Articles

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Natalie S. Callander, Vincent Ribrag, Paul G. Richardson, Ajay K. Nooka, Kevin Song, Katarina Uttervall, Monique C. Minnema, Katja Weisel, Hang Quach, Chang-Ki Min, Marc S. Ballas, Xiaofang Li, Nirav Ratia, Morrys Kaisermann, Beata Holkova, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 897.

https://doi.org/10.1182/blood-2021-152662

Published: 2021

Journal Articles

Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

Shanee Chung, Jennifer White, Cynthia L. Toze, Heather J. Sutherland, David Sanford, Judith Anula Rodrigo, Thomas J. Nevill, Sujaatha Narayanan, Stephen H. Nantel, Florian Kuchenbauer, Kevin A. Hay, Donna L. Forrest, Yasser Abou Mourad, Kevin Song, Maryse Power

Blood (2021) 138 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2021-154492

Published: 2021

Journal Articles

Identification of Previously Unrecognized Multiple Myeloma Risk Subgroups with a Novel Biological Disease Stratifier

Afsaneh M. Shariatpanahi, Sarah Grasedieck, Matthew C. Jarvis, Faezeh Borzooee, Reuben S. Harris, Mani Larijani, Kevin Song, Arefeh Rouhi, Florian Kuchenbauer

Blood (2021) 138 (Supplement 1): 4718.

https://doi.org/10.1182/blood-2021-148718

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology

Henry S. Ngu, Laura K Hilton, Judith Anula Rodrigo, Diego Villa, Alina S. Gerrie, Kevin Song, Pedro Farinha, Graham W. Slack, Kerry J. Savage, David W. Scott, Laurie H. Sehn

Blood (2021) 138 (Supplement 1): 2499.

https://doi.org/10.1182/blood-2021-149049

Published: 2021

Journal Articles

Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)

Henry S. Ngu, Stephen Parkin, David W. Scott, Diego Villa, Alina S. Gerrie, Cynthia L. Toze, Maryse Power, Graham W Slack, Joseph M. Connors, Kevin Song, Laurie H. Sehn, Kerry J. Savage

Blood (2021) 138 (Supplement 1): 624.

https://doi.org/10.1182/blood-2021-146352

Published: 2021

Journal Articles

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139182

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

NARROW

Genetic Variations in Multiple Myeloma with Extramedullary Disease

Real-World Outcomes of Pfts in Screening for Lung Involvement in Chronic Gvhd Post-Allogeneic Stem Cell Transplant: A Retrospective Study of 387 Patients in British Columbia, Canada

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Improvement in Survival of Patients with FLT3 Mutated Acute Myeloid Leukemia: Results from a Retrospective Canadian Cohort

British Columbia Experience in Allogeneic Stem Cell Transplantation for Myelofibrosis with or without Pre-Transplant Ruxolitinib

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study

Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

Identification of Previously Unrecognized Multiple Myeloma Risk Subgroups with a Novel Biological Disease Stratifier

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology

Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only